Sun Pharma inches up as the company settles a patent litigation
Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a licensc to Celgenes patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022.